Latest Insider Transactions at Envista Holdings Corp (NVST)
This section provides a real-time view of insider transactions for Envista Holdings Corp (NVST). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Envista Holdings Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Envista Holdings Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 25
2025
|
Stefan Nilsson President, Nobel Biocare |
SELL
Payment of exercise price or tax liability
|
Direct |
804
-1.44%
|
$16,884
$21.12 P/Share
|
|
Aug 25
2025
|
Eric D. Hammes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,654
-7.33%
|
$160,734
$21.12 P/Share
|
|
Aug 25
2025
|
Robert Befidi President, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
3,454
-7.06%
|
$72,534
$21.12 P/Share
|
|
Aug 25
2025
|
Veronica Acurio President, Orthodontics |
SELL
Payment of exercise price or tax liability
|
Direct |
5,422
-9.73%
|
$113,862
$21.12 P/Share
|
|
Aug 25
2025
|
Mischa Reis SVP, Strategy & Bus. Dev. |
SELL
Open market or private sale
|
Direct |
15,000
-31.66%
|
$315,000
$21.6 P/Share
|
|
Jul 14
2025
|
James Andrew Pierce Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,155
+50.0%
|
-
|
|
Jun 10
2025
|
R Scott Huennekens Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,370
+17.13%
|
-
|
|
Jun 10
2025
|
Barbara B. Hulit Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+11.58%
|
-
|
|
Jun 10
2025
|
Christine A Tsingos Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+17.12%
|
-
|
|
Jun 10
2025
|
Wendy Carruthers Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+17.11%
|
-
|
|
Jun 10
2025
|
Vivek Jain Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+19.33%
|
-
|
|
Jun 10
2025
|
Daniel Raskas Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+18.96%
|
-
|
|
Jun 10
2025
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+18.96%
|
-
|
|
May 25
2025
|
Paul A Keel Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,787
-3.09%
|
$204,592
$16.72 P/Share
|
|
Feb 26
2025
|
Mischa Reis SVP, Strategy & Bus. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
8,475
+15.17%
|
-
|
|
Feb 25
2025
|
Mark E Nance General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
18,155
+20.15%
|
-
|
|
Feb 25
2025
|
Mark E Nance General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,691
-6.42%
|
$73,820
$20.66 P/Share
|
|
Feb 25
2025
|
Eric D. Hammes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,735
+13.09%
|
-
|
|
Feb 25
2025
|
Robert Befidi President, Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
10,290
+17.37%
|
-
|
|
Feb 25
2025
|
Robert Befidi President, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,123
-2.82%
|
$22,460
$20.66 P/Share
|
|
Feb 25
2025
|
Stefan Nilsson President, Nobel Biocare |
BUY
Grant, award, or other acquisition
|
Direct |
10,290
+15.58%
|
-
|
|
Feb 25
2025
|
Veronica Acurio President, Orthodontics |
BUY
Grant, award, or other acquisition
|
Direct |
10,290
+15.58%
|
-
|
|
Feb 25
2025
|
Paul A Keel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,830
+13.71%
|
-
|
|
Feb 25
2025
|
Mischa Reis SVP, Strategy & Bus. Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,813
-8.93%
|
$76,260
$20.66 P/Share
|
|
Feb 25
2025
|
Faez C Kaabi Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,685
+16.23%
|
-
|
|
Feb 25
2025
|
Faez C Kaabi Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,319
-9.68%
|
$86,380
$20.66 P/Share
|
|
Nov 01
2024
|
Paul A Keel Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
53,996
-13.41%
|
$1,079,920
$20.94 P/Share
|
|
Sep 17
2024
|
Mischa Reis SVP, Strategy & Bus. Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
812
-1.87%
|
$15,428
$19.0 P/Share
|
|
Aug 25
2024
|
Robert Befidi President, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
3,454
-7.99%
|
$62,172
$18.7 P/Share
|
|
Aug 25
2024
|
Eric D. Hammes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,175
+41.98%
|
-
|
|
Aug 13
2024
|
Paul A Keel Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+6.93%
|
$480,000
$16.87 P/Share
|
|
Aug 12
2024
|
Eric D. Hammes Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
24,532
+50.0%
|
$392,512
$16.33 P/Share
|
|
Jul 15
2024
|
Mark E Nance General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
491
-0.85%
|
$7,365
$15.94 P/Share
|
|
Jun 25
2024
|
Stephen Keller Principal Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+36.74%
|
-
|
|
May 25
2024
|
Paul A Keel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
372,605
+47.36%
|
-
|
|
May 25
2024
|
Eric Conley SVP, Orthodontics |
SELL
Payment of exercise price or tax liability
|
Direct |
642
-1.19%
|
$11,556
$18.25 P/Share
|
|
May 21
2024
|
Christine A Tsingos Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+20.08%
|
-
|
|
May 21
2024
|
Vivek Jain Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+23.32%
|
-
|
|
May 21
2024
|
R Scott Huennekens Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,170
+20.44%
|
-
|
|
May 21
2024
|
Barbara B. Hulit Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+12.69%
|
-
|
|
May 21
2024
|
Daniel Raskas Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+22.76%
|
-
|
|
May 21
2024
|
Wendy Carruthers Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+20.07%
|
-
|
|
May 21
2024
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+22.76%
|
-
|
|
Apr 15
2024
|
Barbara B. Hulit Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,065
+18.06%
|
-
|
|
Mar 15
2024
|
Barbara B. Hulit Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,705
+20.21%
|
-
|
|
Feb 25
2024
|
Amir Aghdaei Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,570
+13.52%
|
-
|
|
Feb 25
2024
|
Amir Aghdaei Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
33,367
-11.3%
|
$734,074
$22.65 P/Share
|
|
Feb 25
2024
|
Eric Conley SVP, Orthodontics |
BUY
Grant, award, or other acquisition
|
Direct |
7,730
+12.55%
|
-
|
|
Feb 25
2024
|
Eric Conley SVP, Orthodontics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,241
-2.62%
|
$27,302
$22.65 P/Share
|
|
Feb 25
2024
|
Robert Befidi President, Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
9,385
+17.83%
|
-
|